Screener

Deferred Revenue

Name: Rigel Pharmaceuticals Deferred Revenue by Products & Services
Creator: OpenCapital
License: https://www.opencapital.sh/terms

Rigel Pharmaceuticals·Products & Services·2 segments·Rolls up to Contract Liabilities

Breakdown

Segment	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
fostamatinib	$1.4M	$1.4M	$1.4M	$3M	$1.4M	$1.4M	$1.4M	$1.4M
ocadusertib	$0	$0	$0	$0	$0	$0	$0	$0
Total	—	—	—	—	—	—	—	—

fostamatinibView metric